Roche Wins Expanded European Approval for Pegasys

The European Medicines Agency, or EMA, has awarded Big Pharma Roche (NASDAQOTH: RHHBY  ) expanded approval for its antiviral Pegasys, alongside ribavirin, in treating chronic hepatitis C virus, or HCV. The EMA's expanded approval will now allow Roche to treat HCV-positive children aged 5 and older with the drug who have not yet begun treatment, according to a statement from the company.

Roche first won European approval for Pegasys in treating adults with chronic HCV more than a decade ago; regulators in China and the U.S. have approved it as well. Around 65,000 European children suffer from chronic HCV; while Roche states that many sufferers of the disease show few if any symptoms, it is progressive and can afflict patients with life-threatening ailments such as liver damage.

Dr. Hal Barron, Roche's chief medical officer and global product development Head  talked about the new indication’s benefit for children with the disease, saying in the release: “Hepatitis C can ultimately lead to the development of advanced liver disease if left untreated. This approval provides doctors and parents of children as young as five with a treatment combination for this infection.”


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2324069, ~/Articles/ArticleHandler.aspx, 11/24/2014 3:12:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement